FDA Standardizing REMS Re-Enrollment Procedures

Common registration site for participants in REMS was endorsed by several panel members during a joint meeting of the Drug Safety and Risk Management and Dermatologic and Ophthalmic Drugs Advisory Committees.

FDA is developing a standardized policy on how frequently participants in Risk Evaluation and Mitigation Strategy programs should re-enroll and recertify in order to keep their participation current.

The policy is part of FDA efforts to standardize REMS programs in response to stakeholder complaints about the burden on the health care community that results from varying requirements among...

More from US FDA Performance Tracker

More from Regulatory Trackers